Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 December;52(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 December;52(4):378-87

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  MIBG IN DIAGNOSIS AND THERAPY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 December;52(4):378-87

language: English

Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders

Nakajima K. 1, Yoshita M. 2, Matsuo S. 1, Taki J. 1, Kinuya S. 1

1 Department of Nuclear Medicine Kanazawa University Hospital, Kanazawa, Japan
2 Department of Neurology Kanazawa University Hospital, Kanazawa, Japan


FULL TEXT  REPRINTS


Iodine-123-labeled metaiodobenzylguanidine (MIBG) has a history of over 20 years as a marker of myocardial sympathetic activity in Japan and has been used for various cardiac diseases. Aside from conventional utilities in patients with cardiac diseases, including ischemic heart diseases, cardiomyopathy, heart failure and diabetes, neurological disorders have recently been drawing special attention. The [123I]MIBG study showed markedly decreased myocardial uptake in Parkinson’s disease, dementia with Lewy bodies and pure autonomic failure, which is a common feature of Lewy-body diseases. The MIBG study can be used for differentiating patients with extrapyramidal signs and dementia. The unique application of MIBG in movement disorders and related neurological diseases is one of its most common uses in Japan, and further studies are expected worldwide.

top of page